猪又峰彦 (Minehiko Inomata) - マイポータル

基本情報

J-GLOBAL ID: 202401016593814393
researchmap会員ID: R000076560

論文

An observational study on the efficacy of targeted therapy for pulmonary sarcomatoid carcinoma

Takeshi Tsuda, Tomomi Ichikawa, Masahiro Matsumoto, Isami Mizusihima, Kenji Azechi, Naoki Takata, Nozomu Murayama, Kana Hayashi, Takahiro Hirai, Zenta Seto …

Discover Oncology 15(1) 2024年8月29日
Comparing the Effectiveness of Afatinib and Osimertinib for Patients With PD-L1-positive EGFR-mutant Non-small Cell Carcinoma

MINEHIKO INOMATA, YOSUKE KAWASHIMA, RYOTA SAITO, DAISUKE MORINAGA, HITOMI NOGAWA, MASAMICHI SATO, YOHEI SUZUKI, SATORU YANAGISAWA, TAKASHI KIKUCHI, DAISUKE JINGU …

Cancer Diagnosis & Prognosis 4(4) 515-520 2024年7月1日
Comparison of the efficacy of first‑/second‑generation EGFR‑tyrosine kinase inhibitors and osimertinib for EGFR‑mutant lung cancer with negative or low PD‑L1 expression

Minehiko Inomata, Shuhei Minatoyama, Naoki Takata, Kana Hayashi, Takahiro Hirai, Zenta Seto, Kotaro Tokui, Chihiro Taka, Seisuke Okazawa, Kenta Kambara …

Molecular and Clinical Oncology 20(6) 2024年5月1日
Risk and survival of patients with non-small cell lung cancer and pre-existing autoimmune disorders receiving immune checkpoint blockade therapy

Asao T, Shukuya T, Uemura K, Kitadai R, Yamamoto G, Mouri A, Tamaoka M, Imai R, Tsukita Y, Isobe K その他

Lung Cancer 194 2024年
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis

Nishioka N, Imai H, Endo M, Notsu A, Doshita K, Igawa S, Yokouchi H, Ninomiya T, Tokito T, Soda S その他

Targeted Oncology 19(3) 423-433 2024年
Pure Red Cell Aplasia and Chromosomal Abnormality in a Patient With Lung Adenocarcinoma Receiving Immune Checkpoint Inhibitors

Hirai T, Inomata M, Minatoyama S, Hashizume M, Takata N, Hayashi K, Seto Z, Tokui K, Taka C, Okazawa S その他

In Vivo 38(3) 1509-1511 2024年
Immune Checkpoint Inhibitor Therapy for Patients With Non-small Cell Lung Cancer Ineligible for Platinum Doublet Chemotherapy

Inomata M, Minatoyama S, Takata N, Hayashi K, Hirai T, Seto Z, Tokui K, Taka C, Okazawa S, Kambara K その他

Anticancer Research 44(3) 1241-1245 2024年
Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers

NOVELTY Scientific Community, NOVELTY study Investigators

Journal of Allergy and Clinical Immunology: In Practice 12(4) 970-982 2024年
A retrospective study of the efficacy of combined EGFR‑TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR‑TKI monotherapy for PD‑L1‑positive EGFR‑mutant non‑small cell lung cancer: North Japan Lung Cancer Study Group 2202.

Minehiko Inomata, Yosuke Kawashima, Ryota Saito, Daisuke Morinaga, Hitomi Nogawa, Masamichi Sato, Yohei Suzuki, Satoru Yanagisawa, Takashi Kikuchi, Daisuke Jingu …

Oncology letters 26(2) 334-334 2023年8月
Pulmonary abscess caused by Cladosporium cladosporioides after receiving outpatient chemotherapy

Kaneda M, Nagaoka K, Kawasuji H, Matsunaga K, Inomata M, Miyazaki Y, Nakashima A, Yamamoto Y

Journal of Infection and Chemotherapy 29(10) 993-996 2023年
Peripheral CD4 memory T cells predict the efficacy of immune checkpoint inhibitor therapy in patients with non-small cell lung cancer

Inomata M, Matsumoto M, Takata N, Hayashi K, Seto Z, Hirai T, Tokui K, Taka C, Okazawa S, Kambara K その他

Scientific Reports 13(1) 2023年
Efficacy of immune checkpoint inhibitor therapy in patients with pulmonary sarcomatoid carcinoma in clinical practice

Inomata M, Tsuda T, Ichikawa T, Matsumoto M, Mizushima I, Azechi K, Takata N, Murayama N, Hayashi K, Hirai T その他

Thoracic Cancer 14(17) 1618-1623 2023年
Cluster Analyses From the Real-World NOVELTY Study

NOVELTY Scientific Community, NOVELTY study Investigators

Journal of Allergy and Clinical Immunology: In Practice 11(9) 2803-2811 2023年
Chronic Airways Assessment Test

for the NOVELTY Scientific Community, and the NOVELTY study investigators

Respiratory Research 24(1) 2023年
Associations of immune checkpoint inhibitor therapy efficacy with clinical parameters and tumor-infiltrating cd68-positive cell counts in patients with egfr-mutant non-small cell lung cancer

Tsuda T, Suzuki K, Inomata M, Hayashi K, Mizushima I, Tokui K, Taka C, Okazawa S, Kambara K, Imanishi S その他

Molecular and Clinical Oncology 18(5) 2023年
Association Between the Severity of Immune-related Adverse Events and the Prognosis in Patients With Non-small Cell Lung Cancer Receiving Treatment With Immune Checkpoint Inhibitors

Inomata M, Matsumoto M, Hayashi K, Seto Z, Hirai T, Tokui K, Taka C, Okazawa S, Kambara K, Imanishi S その他

Anticancer Research 43(7) 3241-3246 2023年
A retrospective study of the efficacy of combined EGFR-TKI plus VEGF inhibitor/cytotoxic therapy vs. EGFR-TKI monotherapy for PD-L1-positive EGFR-mutant non-small cell lung cancer

Inomata M, Kawashima Y, Saito R, Morinaga D, Nogawa H, Sato M, Suzuki Y, Yanagisawa S, Kikuchi T, Jingu D その他

EGFR-TKI monotherapy for PD-L1-positive EGFR-mutant non-small cell lung cancer: North Japan Lung Cancer Study Group 2202 26(2) 2023年
Association of Tumor PD-L1 Expression With Time on Treatment Using EGFR-TKIs in Patients With EGFR-Mutant Non-small Cell Lung Cancer

MINEHIKO INOMATA, MASAHIRO MATSUMOTO, ISAMI MIZUSHIMA, ZENTA SETO, KANA HAYASHI, KOTARO TOKUI, CHIHIRO TAKA, SEISUKE OKAZAWA, KENTA KAMBARA, SHINGO IMANISHI …

Cancer Diagnosis & Prognosis 2(3) 324-329 2022年5月3日
Treatable traits in the NOVELTY study

for the NOVELTY Study Investigators

Respirology 27(11) 929-940 2022年
The burden of mild asthma

NOVELTY investigators

Respiratory Medicine 200 2022年

もっとみる

MISC

PD-L1陽性EGFR陽性NSCLCに対するEGFR-TKI併用療法の有効性:NJLCG2202

齋藤良太, 猪又峰彦, 川嶋庸介, 森永大亮, 野川ひとみ, 佐藤正道, 鈴木洋平, 柳澤悟, 菊池崇史, 神宮大輔 …

日本肺癌学会学術集会号(CD-ROM) 64th 2023年